US Patent Issued to Mezzion Pharma, The Children's Hospital of Philadelphia on March 17 for "Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions" (Illinois, Pennsylvania Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,576,081, issued on March 17, was assigned to Mezzion Pharma Co. Ltd. (Seoul, South Korea) and The Children's Hospital of Philadelphia (Philadelphia).

"Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in single ventricular heart disease, using udenafil compositions" was invented by James L. Yeager (Lake Forest, Ill.), David J. Goldberg (Philadelphia) and Stephen M. Paridon (Strafford, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have un...